Category: 8. Health

  • Do we really need a tetanus-diphtheria booster every 10 years? New research says maybe not

    Do we really need a tetanus-diphtheria booster every 10 years? New research says maybe not

    For generations, adults in the U.S. have been told to roll up their sleeves for a tetanus and diphtheria booster every 10 years. But new research from Oregon Health & Science University suggests this long-standing advice may be outdated — and unnecessarily costly.

    In a study published Tuesday, OHSU scientists argue that adults who completed their childhood vaccinations may not need tetanus or diphtheria boosters nearly as often as previously thought. Their findings suggest protection lasts far longer for most healthy adults — at least 30 years, and possibly for life.

    “Why keep vaccinating adults every 10 years? It’s just burned into our brains when the evidence shows you don’t have to,” said lead author Dr. Mark K. Slifka, a professor at OHSU’s Oregon National Primate Research Center.

    The U.S. has recommended a 10-year booster schedule for tetanus-diphtheria since the 1960s. But Slifka said this guidance hasn’t kept pace with mounting evidence that immunity to these diseases — now rare in the U.S. thanks to widespread childhood vaccination — doesn’t require such frequent upkeep.

    “Tetanus and diphtheria are among our most successful vaccines,” he said. “Their effectiveness has virtually eliminated these diseases in countries with high childhood vaccination coverage.”

    Tetanus, a severe bacterial disease caused by spores commonly found in soil, manure or dust, now occurs in the U.S. at a rate of less than one case per 10 million people annually. Diphtheria, a highly contagious bacterial infection, is even more rare, with just seven cases reported nationwide over the past 20 years.

    Oregon’s last tetanus case occurred in 2017, when an unvaccinated 6-year-old boy nearly died after scraping his forehead. Before that, the state hadn’t seen a case in 30 years.

    Slifka’s latest study, published in the journal Clinical Microbiology Reviews, builds on nearly two decades of research tracking immunity in individuals and across populations. His findings suggest that for adults who received the standard five-dose childhood vaccine series, immunity often lasts for life — making routine boosters largely unnecessary.

    If you purchase a product or register for an account through a link on our site, we may receive compensation. By using this site, you consent to our User Agreement and agree that your clicks, interactions, and personal information may be collected, recorded, and/or stored by us and social media and other third-party partners in accordance with our Privacy Policy.

    Continue Reading

  • Playing an instrument may help protect brain against ageing, study finds

    Playing an instrument may help protect brain against ageing, study finds

    Playing a musical instrument could help protect the brain against age-related decline, new research has suggested.

    Older adults with long-term musical training performed better at understanding speech in noisy environments and showed brain connectivity patterns closer to younger people, according to a study published in the journal PLOS Biology.

    Researchers from Baycrest Academy for Research and Education in Canada and the Chinese Academy of Sciences used functional MRI scans to compare brain activity in 25 older musicians, 25 older non-musicians and 24 young non-musicians.

    The participants were asked to identify syllables masked by background noise, a task that typically becomes harder with age.

    While older non-musicians showed the usual age-related increase in neural activity and connectivity – a sign that the brain is working harder to compensate for decline – older musicians maintained a more “youth-like” pattern.

    The strength of connections in certain brain networks also correlated with better performance on the speech-in-noise task, the study found.

    Older adults with long-term musical training performed better at understanding speech in noisy environments and showed brain connectivity patterns closer to younger people (Getty Images)

    Older adults with long-term musical training performed better at understanding speech in noisy environments and showed brain connectivity patterns closer to younger people (Getty Images)

    Older adults with long-term musical training performed better at understanding speech in noisy environments and showed brain connectivity patterns closer to younger people (Getty Images)

    The findings support what the researchers call the “Hold-Back Upregulation” hypothesis. This is when the cognitive reserve built through musical training helps the brain hold onto its younger functional features, instead of simply compensating for loss.

    Dr Yi Du, co-author of the study, said: “Just like a well-tuned instrument doesn’t need to be played louder to be heard, the brains of older musicians stay finely tuned thanks to years of training.

    “Our study shows that this musical experience builds cognitive reserve, helping their brains avoid the usual age-related overexertion when trying to understand speech in noisy places.”

    The authors said that although the study cannot prove cause and effect, it adds to growing evidence that positive lifestyle choices, such as musical training, higher education and bilingualism, can help the brain cope better with ageing.

    Dr Lei Zhang, another co-author, added: “A positive lifestyle helps older adults cope better with cognitive ageing, and it is never too late to take up, and stick with, a rewarding hobby such as learning an instrument.”

    The scientists are now planning to explore whether other activities, such as exercise and multilingualism, could offer similar benefits.

    Continue Reading

  • Dogs Successfully Detect Parkinson's Disease – MedPage Today

    1. Dogs Successfully Detect Parkinson’s Disease  MedPage Today
    2. Skin swabs may detect Parkinson’s up to seven years early  Open Access Government
    3. AI Nose Could Detect Parkinson’s Through Smell Alone  ScienceBlog.com
    4. Bio Detection Dogs Successfully Detect Parkinson’s Disease by Odour, Study Finds | Newswise  Newswise
    5. Woman who smelled husband’s Parkinson’s 12 years early helps develop new test  MSN

    Continue Reading

  • Israeli scientists create digital twin that can predict diseases before symptoms appe

    Israeli scientists create digital twin that can predict diseases before symptoms appe

    Before we make life-changing decisions, we often run through different scenarios in our minds to predict possible outcomes. But when it comes to our health, forecasting the future becomes especially difficult. Will a certain treatment work? Will a dietary change improve well-being?

    Now, researchers at the Weizmann Institute of Science in Israel have developed a tool that can do just that—simulate and predict medical outcomes tailored to each person. Powered by advanced artificial intelligence, their new “digital twin” model can forecast future diseases, flag potential health risks before symptoms emerge, and recommend personalized treatment paths. The breakthrough, published Tuesday in the journal Nature Medicine, is based on the “Human Phenotype Project,” an ambitious study that gathered vast medical data from more than 13,000 individuals over several years.

    3 View gallery

    בינה מלאכותית, תיאום דיגיטלי

    Artificial Intelligence

    (Photo: shutterstock)

    The initiative was launched in 2018 by Professor Eran Segal of the institute’s Department of Computer Science and Applied Mathematics to complement the insights of the Human Genome Project, which began in 1990 and mapped thousands of genes linked to our traits and diseases. But while genes offer part of the picture, Segal’s team wanted to go further, integrating environmental factors, gut microbiome composition, aging processes, and more.

    Participants in the Human Phenotype Project undergo extensive health evaluations every two years for 25 years. These include physical exams, nutritional journals, ultrasound scans, bone density tests, voice recordings, home sleep monitoring, continuous glucose tracking, genetic sequencing, gene expression analysis, protein and metabolic profiling, and microbiome sampling from the gut, mouth and reproductive tract.

    “We wanted to build an Israeli biobank that collects multiple layers of information—molecular and clinical—and follows people over time,” said Dr. Smadar Shilo, a senior physician and pediatric endocrinologist at Schneider Medical Center, who helped lead the project during her doctoral work in Segal’s lab and continues to work on it today. “The goal is to identify biomarkers that can predict future diseases and build a framework for predictive, personalized medicine.”

    According to Shilo, combining layers of data such as genetics, metabolites and immune system metrics could help detect illnesses long before they emerge. “If I track a person and collect all their baseline data, I can look for biomarkers that preceded a later diagnosis. That’s the ultimate goal—early prediction using AI-driven tools,” she explains.

    Since its launch, the Human Phenotype Project has grown to more than 30,000 registered participants, with the aim of reaching 100,000. The team has also opened satellite branches in Japan and the United Arab Emirates to diversify the dataset and study ethnic, cultural and environmental variability.

    The data has already been fed into a sophisticated AI model developed by researchers, including Dr. Lee Reicher and Shilo. The model—built on a platform by Pheno.AI—learns how 17 body systems typically change over a lifetime and can detect abnormalities. It assigns each system a “biological age” score based on sex, BMI and chronological age, then flags deviations that may indicate higher disease risk.

    3 View gallery

    ד"ר סמדר שילה ופרופ' ערן סגלד"ר סמדר שילה ופרופ' ערן סגל

    Dr. Lee Reicher, Prof. Eran Segal, and Dr. Smadar Shilo

    (Photo: Weizmann Institute of Science)

    “For example, we can isolate cardiovascular parameters—like ultrasound imaging of neck arteries or ECG data—and develop a model to predict that specific system’s biological age,” said Shilo. The tool can spot deviations before symptoms appear. Tracking participants’ glucose levels over time, the team found that some 40% of those considered healthy by current fasting glucose standards exhibited prediabetic patterns when analyzed more deeply.

    “Thanks to unique continuous glucose monitoring data collected from thousands of people, we were able to define new norms for these measurements,” said Shilo. “We can now observe how values shift with age and distinguish between male and female trends.”

    Segal noted: “Biological aging in men tends to increase linearly, but in women we see a sharp jump during their 50s. Menopause appears to reset the biological clock in significant ways. For instance, bone density decline correlates more with time since menopause than with chronological age. Our markers can help detect early signs of menopause and guide hormonal treatment accordingly.”

    The diversity of the Israeli population is another key strength. “This is a unique aspect of the project,” said Shilo. “We can compare data from people with different ancestral origins to see how much is driven by genetics versus other factors.” She added that while genetic data can predict ethnic origin quite accurately—identifying Ashkenazi or Yemenite ancestry, for example—microbiome data cannot, indicating it’s shaped more by shared environments than genes.

    Ultimately, the project aims to pioneer a new era of predictive medicine through a comprehensive AI model trained on the entire dataset of each participant. This model—a true digital twin—is currently being developed by Ph.D. candidate Guy Lutzker. Using generative AI techniques, the system is trained by hiding individual data points and challenging itself to infer the missing pieces. Over time, it builds an integrated health profile capable of forecasting likely medical events years in advance.

    3 View gallery

    בינה מלאכותית לרפואה מותאמת אישיתבינה מלאכותית לרפואה מותאמת אישית

    “This has huge implications—from simulating the effect of a drug before prescribing it to modeling the impact of lifestyle changes,” said Shilo. “That’s the vision: to tailor medical decisions to the individual based on their digital twin.”

    The team has already created a model that analyzes glucose data to predict not only future blood sugar levels but also who among prediabetics is at the highest risk of developing full diabetes within two years, giving doctors a chance to intervene early.

    Other tools include “Gluformer,” an AI model trained on over 10 million glucose readings, and COMPRER, which combines retinal images and neck artery scans to predict cardiovascular diseases. “Many studies show that eye vasculature reveals a lot about health. We’re combining multiple datasets to improve predictions,” Shilo explained.

    The true power of these tools lies not only in the scale but in their capacity to integrate complex data that human doctors can’t. “As an endocrinologist, I can’t analyze 10 million glucose readings to reach insights. These models can.”

    Already, the digital twin is being used to test dietary and pharmaceutical interventions tailored to individuals. In the future, the system is expected to integrate all forms of available health data, predict a broad range of conditions, and reduce the trial-and-error phase in treatment selection.

    “This progress is only possible thanks to the Human Phenotype Project’s community of committed participants,” concluded Segal. “We’re even developing an app that will put all this data directly in their hands, offering them a personal health dashboard.”

    “We are living through a period of rapid transformation,” he added. “The worlds of medicine and health are on the brink of becoming AI-driven, and our project may serve as a global engine for innovation. I want to thank every participant—your contribution is powering the future of medicine.”


    Continue Reading

  • Consuming more protein may protect patients taking anti-obesity drug from muscle loss – FirstWord Pharma

    1. Consuming more protein may protect patients taking anti-obesity drug from muscle loss  FirstWord Pharma
    2. Protein Safeguards Muscle in Semaglutide Weight-Loss Therapy  Medscape
    3. What to know about protein intake while on weight-loss medication  MSN
    4. Veru survey highlights muscle loss concerns among GLP-1 users, as lean mass-preserving med plows ahead  Fierce Pharma
    5. Semaglutide melts fat—but may quietly strip away your strength  ScienceDaily

    Continue Reading

  • New Adhesive Unveiled for Wearable Medical Devices

    New Adhesive Unveiled for Wearable Medical Devices

    Wearable healthcare devices, such as glucose monitors and heart monitors, are popular due to their ability to gather real-time data that supports users’ health and safety.

    However, despite their benefits, these devices must often be worn on the arms or chest for a long period of time. They can irritate the skin, cause allergic reactions, and become obstructed by moisture and sweat.

    Dr. Jaime Grunlan, Leland T. Jordan ’29 Chair Professor in the J. Mike Walker ’66 Department of Mechanical Engineering at Texas A&M University, has developed a new type of adhesive — the first of its kind — that could offer a more comfortable alternative for medical device users.

    This research was recently published in Macromolecular Rapid Communications.

    For many years, Grunlan has worked to develop one-pot polyelectrolyte-complex (PEC) coatings for flame-retardant treatments on materials such as foam, fabric and wood. When he realized the inherent properties of PECs, such as their stickiness, he saw an opportunity to expand the use of PEC adhesive to wearable biomedical devices.

    Most current technologies use hydrophobic, pressure-sensitive adhesives to adhere to various parts of the body. Although practical and often necessary, these commercial-grade devices use solvent-based adhesives consisting of acrylates, methacrylates, or colophonium, which can irritate the skin, with users reporting rashes, inflammation, itchiness and redness.

    In contrast, since PECs are water-based, the potential discomfort and irritation on the skin could be reduced. Additionally, its water-based nature would mean moisture would likely improve adhesion. For example, the salt in sweat could increase the level of adhesion.

    “To our knowledge, no one has used a PEC as an adhesive for wearable medical devices,” said Grunlan. “We were able to develop and patent a PEC that can match the adhesive strength of 3M Tegaderm adhesive. Tegaderm is a ‘cyanoacrylate’ polymer that is solvent-based, but many people complain due to the skin irritation that often comes along.”

    This work is still in its early stages but offers a unique alternative to traditional adhesives with many positive benefits for people with diabetes, heart problems, sleep disorders and more.

    Contributors to the research include formal doctoral students, Drs. Maya Montemayor and Ethan Iverson. Additionally, Dr. Balakrishna Haridas from the Department of Biomechanical Engineering at Texas A&M and his lab performed biocompatibility testing to publish this work.

    The research was made possible with the support of Dr. Gerard L. Cote through the Precise Advanced Technologies and Health Systems for Underserved Populations Engineering Research Center at Texas A&M and is part of an Army Phase II SBIR.

    By Michelle Revels, Texas A&M University College of Engineering

    /Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.

    Continue Reading

  • DZP Significantly Improves Disease Activity, Fatigue in People With SLE

    DZP Significantly Improves Disease Activity, Fatigue in People With SLE

    Eric F. Morand, MBBS

    Credit: Monash University

    Dapirolizumab pegol (DZP) improved disease activity and fatigue in people with moderate-to-severe systemic lupus erythematosus (SLE), in new data from the phase 3 PHOENYCS GO trial.

    These new data were presented at last month’s European Alliance of Associations for Rheumatology (EULAR) Congress 2025 held in Barcelona, Spain, by Eric F. Morand, MBBS, Head of the Monash Health Rheumatology Unit, Monash University, Australia.

    Morand and colleagues found that at Week 48, 40.9% of participants receiving DZP plus standard of care (SOC) achieved low disease activity, more than double the rate in the SOC-only group (19.6%; nominal* P <.0001). As early as Week 12, significantly more participants on DZP plus SOC achieved low lupus disease activity state (LLDAS) versus SOC alone (nominal* P <.05). Additionally, 23.6% of the DZP group maintained low disease activity in ≥50% of visits over 48 weeks, compared to 15.9% with SOC alone (nominal* P = .1042). At Week 48, 19.2% of participants receiving DZP achieved remission (DORIS criteria), compared to 8.4% in the SOC-only group (nominal* P = .0056).

    HCPLive spoke with Morand to learn more about the findings and DZP’s potential in treating SLE. He also discussed the therapeutic potential of CD40L inhibition and the importance of minimizing glucocorticoid exposure.

    HCPLive: With improvements in BICLA, disease activity, fatigue and others, from your perspective, what are the most meaningful findings and outcomes seen with DZP from PHOENYCS GO?

    Morand: The BICLA and fatigue results are both equally exciting. BICLA is a validated way to measure response to therapy in an SLE trial and has been used to support the registration of anifrolumab – so these results are very supportive for the potential for DZP to be registered in the future. The Fatigue results are different – these symptoms are incredibly important to patients but have been very hard to impact on in the past…the potential to hit on disease activity AND fatigue with one therapy is really going to be welcomed by patients.

    Can you discuss the significance of the LLDAS and DORIS remission endpoints in the context of SLE management today? How do you interpret the magnitude of benefit seen in these measures?

    Attainment of treat to target goals is now enshrined in both the EULAR and ACR guidelines as the goal of treatment because these endpoints have been shown in study after study to be associated with improved long term outcomes including disease activity, flare, damage accrual, quality of life and even mortality. I think the gold standard for a modern lupus therapy should be to show that it safely increases attainment of these end points vs the comparator. In this EULAR abstract we can see very meaningful separation from placebo very soon after starting treatment with DZP, and strong and significant separation across time all the way to last visit.

    Trials in lupus are hard, so we are left needing to interpret results that can only be reported with nominal significance. The LLDAS and remission analysis reported at EULAR were pre-specified analyses, not post hoc, so I think we can be pretty confident in them.

    LLDAS and DORIS achievement requires tapering to low doses of glucocorticoids. Can you discuss why this is important for long-term SLE management?

    The reason that glucocorticoid ceilings are included in both LLDAS and DORIS remission is that glucocorticoid use contributes in a dose-dependent way to net harm to patient including via damage accrual. Again, current guidelines stress minimizing glucocorticoid exposure and attainment of LLDAS and DORIS are validated metrics to ensure this is achieved while disease control is maintained.

    What do these data tell us about the therapeutic potential of CD40L inhibition in SLE?

    It is a positive phase 3 trial – evidence does not get much better than this. Trials in SLE are really hard to do, as the disease is heterogenous and endpoints disfavor success – this means a positive result has basically happened against the odds and is meaningful. How DZP fits into the treatment paradigm remains to be seen as the pipeline has lots of other interesting medicines in development which together will change the landscape very greatly in the next handful of years. Regardless, these data strongly suggest that CD40L has a real place in our care paradigm.

    In your opinion, what gaps in current SLE care could DZP meaningfully address if approved and how could it potentially shift the treatment landscape?

    Our current biologicals achieve LLDAS in only 30% of patients after one year, and remission in around half that – so it is clear there is a lot of room for improvement with the option of additional therapies to try. It isn’t currently possible to say one biologic is ‘better’ than another, but as we get used to the patient profiles that may respond differently to differently targeted medicines, or differences in safety profile that may influence our choice based on patients’ comorbidities, things will get clearer. On the basis that DZP clearly increases attainment of treatment goals, it will have a significant role if it gains regulatory approval.

    Transcript has been edited for clarity.

    REFERENCE
    Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity. Biogen. News release. June 12, 2025. https://investors.biogen.com/news-releases/news-release-details/dapirolizumab-pegol-phase-3-data-sle-presented-annual-european

    Continue Reading

  • The HIV Prevention Pipeline | IAS 2025

    The HIV Prevention Pipeline | IAS 2025

    The need for collaboration and community-inclusive practices to advance HIV prevention efforts in the face of significant funding constraints was a focal point of those who spoke during a session at the International AIDS Society meeting in Kigali, Rwanda.

    The session, co-hosted by the Bill & Melinda Gates Foundation, Gilead, Merck, and the Reproductive Health Institute, gathered researchers, advocates and community leaders to address adapting to a changing funding environment for research of HIV prevention. They addressed the evolving landscape of HIV prevention, including oral HIV preexposure prophylaxis (PrEP), HIV vaccines and broadly neutralizing antibodies (bnAbs), a newer area of research.

    They urged attendees of the need to continue with research of HIV prevention despite funding from the United States that is being pulled back. A concern of speakers was the recent termination of 191 HIV-specific grants by the U.S. National Institutes of Health (NIH), which slashed more than $200 million in funding — disrupting early-stage research, behavioral interventions, and vaccine development.

    Nyaradzo Mavis Mgodi, MBChB

    “We saw that $99 million was cut from HIV prevention, including the work that I do in HIV, biomedical products, behavioral interventions and access barriers and key populations were not spared,” Nyaradzo Mavis Mgodi, MB.ChB., biomedical HIV prevention methods, University of Zimbabwe Clinical Trials Research Centre, said during the session. “The cuts have adversely affected us all.”

    Mgodi and other speakers presented key takeaways from the Future of HIV Prevention Clinical Trials Summit, which was held in June 2025 in Johannesburg, South Africa. At the heart of the discussions at the June Summit and at IAS was the urgent push for smarter, more agile clinical trials that keep the focus on community engagement. Speakers stressed the need for innovative trial designs that use modeling and artificial intelligence that can accelerate development without sacrificing inclusivity or scientific rigor.

    Speakers also talked about the HIV prevention pipeline and recent results of trials. Despite the recent approval of lenacapavir as a twice-yearly PrEP, there is still a need for choice in HIV prevention. Developed by Gilead Sciences, lenacapavir (now with the brand name Yeztugo) was approved by the FDA on June 18 as both an oral tablet and as a subcutaneous injection.

    “The context for HIV prevention research is rapidly evolving,” Grace Kumwenda, regional program manager at AVAC in Malawi, said during the session. “We are facing shifting epidemiology. Some populations are seeing lower incidence, and others remain quite underserved. At the same time, how do we design and prioritize research?”

    Oral PrEP

    Merck recently announced that it will begin phase 3 clinical trials of MK-8527, an investigational once-monthly oral for HIV PrEP. The EXPrESSIVE-11 trial will evaluate the safety and efficacy of MK-8527 in 16 countries and will begin enrolling in August 2025.

    MK-8527 is a nucleoside reverse transcriptase translocation inhibitor (NRTTI), and in the trial it will be compared with emtricitabine/tenofovir disoproxil fumarate, which is available as a generic. A branded emtricitabine/tenofovir disoproxil fumarate is marketed as Truvada by Gilead.

    A phase 2 trial of MK-8527 enrolled 350 participants with a low likelihood of HIV-1 exposure, who were randomized to one of three doses of MK-8527 or placebo once monthly for six months. In the trial, the rates of adverse events were similar among those in the MK-8527 arms and those in the placebo arm, and no clinically meaningful changes were seen in laboratory tests, including total lymphocyte and CD4 T-cell counts.

    Rebeca Plank, M.D., senior principal scientist, clinical research at Merck, said during the IAS session that researchers carefully considered the comparator that would be used in EXPrESSIVE-11 trial, consulting community organizations and other stakeholders.

    Originally, researchers considered using Vocabria (cabotegravir), an oral integrase strand transfer inhibitor (INST) that is taken daily when used as PrEP. But MK-8527 will be used monthly, and Plank said researchers were looking for direct comparison.

    “This was done in consultation with various stakeholders from the beginning and even before the protocols really began to be drafted,” Plank said.

    She also pointed out that the comparator was chosen before the approval of lenacapavir, a twice-yearly PrEP. Developed by Gilead Sciences, lenacapavir (now with the brand name Yeztugo) was approved by the FDA on June 18 as both an oral tablet and as a subcutaneous injection.

    Vaccines

    Despite many years of research, a vaccine using active immunization hasn’t been successfully developed because of biological and technical challenges of making an HIV vaccine. Mgodi said there have been some positive signals, especially with RV144. A Thailand study of RV144 conducted almost a decade ago demonstrated that the vaccine was safe and had a statistically significant decrease in HIV infection. But protective immunity appeared to wane, and the vaccine is not currently available.

    Other studies have given a negative result because HIV is highly unstable.

    Some, however, have questioned whether a vaccine is still needed because of the availability of long-acting PrEP such as lenacapavir. Mgodi made the case during her presentation that vaccines would add to the arsenal of HIV prevention.

    “There are people who are not adherent to PrEP, and we know that many people who acquire HIV don’t perceive themselves to be at risk,” she said. “That’s one reason why we need a vaccine as an alternative to PrEP that is focused on specific populations, which really sometimes marginalizes others or stigmatizes others.”

    She said that vaccines have the potential to prevent between 8.4 million and 19 million new HIV infections, depending on efficacy.

    bnAbs

    Research is continuing, however, on passive immunization with broadly neutralizing antibodies, or bnAbs, which are a type of antibody that can recognize and block different HIV strains. Organizations, such as IAVI, and groups funded by the National Institutes of Health (NIH), such as the Scripps Consortium for HIV/AIDS Vaccine Development (CHAVD), are conducting research in this area.

    In May 2025, IAVI and Scripps Research released data from two separate phase 1 trials showing that a targeted vaccine strategy can successfully activate early immune responses relevant to HIV. The trials included nearly 80 participants from both North America and Africa, and the study was published in Science on May 15, 2025.

    One of the trials tested a stepwise vaccination strategy, in which a priming dose and a distinct booster dose were given sequentially to guide the immune system through stages of antibody development. The second trial focused on the priming stage and showed that an initial vaccine dose could successfully activate the desired immune cells in African participants.

    Commercial companies, such as ViiV Healthcare, are also developing bnAbs. In March 2025, ViiV released data from a phase 2b study that N6LS, a bNAb administered every four months, effectively maintained undetectable viral load when combined with Apretude, a long-acting cabotegravir. The study found that the combination kept viral levels suppressed in adults living with HIV who were already stable on treatment. It was also well tolerated by participants.

    Continue Reading

  • Study: No link between vaccine aluminum, health problems

    Study: No link between vaccine aluminum, health problems

    July 14 (UPI) — A new study of more than 1.2 million people found no link between aluminum in childhood vaccines and long-term health problems, including autism, asthma or autoimmune diseases.

    The research, published Monday in the Annals of Internal Medicine, looked at 50 chronic conditions.

    They included 36 autoimmune diseases, nine types of allergies and asthma, and five neurodevelopmental disorders, such as autism and ADHD, NBC News reported.

    Aluminum has long been added to vaccines to help the body build a stronger immune response. But the additive has also become a target for vaccine skeptics, including some public figures who have called it harmful.

    “Our study addresses many of these concerns and provides clear and robust evidence for the safety of childhood vaccines,” senior author Anders Hviid, head of epidemiology research at Statens Serum Institute in Denmark, said.

    “This is evidence that parents need to make the best choices for the health of their children,” he added.

    His team used health records from Denmark’s national registry to study people born between 1997 and 2018. They were followed through the end of 2020.

    Because health data in Denmark is carefully tracked, the team was able to compare kids who received more aluminum in their vaccines before age 2 with those who received less. Unvaccinated children were not part of the study, NBC News said.

    Ross Kedl, a vaccine expert at the University of Colorado Anschutz Medical Campus who reviewed the findings, said this type of large-scale research is only possible in countries like Denmark.

    “[This excellence is] partly because they have, for a long time, had such a unified health system,” Kedl told NBC News. “Everyone is tracked for life from birth and you can go back for many years and ask, ‘Can we find a link between something that happened in the past and in the future?’ “

    The study was, in part, a response to a 2022 U.S. Centers for Disease Control and Prevention-funded study that had suggested a link between aluminum-containing vaccines and asthma. That study has been widely criticized since.

    Experts said it failed to distinguish aluminum in vaccines from aluminum from other sources, such as food, water, air and even breast milk.

    “Aluminum is part of our daily diet and has been since the beginning of time. That is the point people don’t understand,” Michael Osterholm, director of the Center for Infectious Disease Research and Policy at the University of Minnesota, told NBC News.

    Dr. Paul Offit, director of the Vaccine Education Center at Children’s Hospital of Philadelphia, said the earlier study didn’t properly account for outside factors.

    “If you are looking at people who got vaccines that contained aluminum versus those who had fewer, you have to control for confounding factors, you need to know that the only different source of aluminum these people received was from those vaccines,” Offit said.

    Aluminum is used in some vaccines as an adjuvant – a substance that helps trigger a stronger immune response.

    “An adjuvant is a substance that alerts the body’s immune response to the vaccine’s antigen,” Kedl explained. “Without adjuvants, you actually create tolerance, which is the opposite effect of what you want a vaccine to do.”

    In the U.S., aluminum salts are used in vaccines for diphtheria, tetanus and pertussis (DTaP), as well as for HPV, hepatitis B and pneumonia.

    “The aluminum that is in vaccines is in the form of extremely small amounts of aluminum salts, which is not the same as elemental aluminum which is a metal,” Hviid said. “It’s really important for parents to understand that we are not injecting metal into children.”

    Most of the aluminum leaves the body within two weeks, but trace amounts can stay for years.

    Experts say no single study can prove something is safe, but this new research adds to years of research showing that aluminum in vaccines is not harmful.

    “One study does not make for a safe vaccine supply or not,” Osterholm said. “It’s the accumulative data that comes from many studies that have been done, that together demonstrate the safety of vaccines.”

    Hviid, meanwhile, pointed out that vaccines containing aluminum are “the backbone” of childhood immuniation programs.

    “It is critically important that we keep politics and science apart in this issue,” he said. “If not, it is the children, including U.S. children, who are going to suffer the consequences.”

    More information

    Children’s Hospital of Philadelphia has more on aluminum in vaccines.

    Copyright © 2025 HealthDay. All rights reserved.

    Continue Reading

  • Type 2 Diabetes and Obesity in Teens Could Increase Risk of Osteoporosis

    Type 2 Diabetes and Obesity in Teens Could Increase Risk of Osteoporosis

    Children and adolescents with obesity and type 2 diabetes (T2D) could experience a greater risk of fractures and osteoporosis later in life, as both conditions are linked to an interference with bone development. The findings, which were presented at the Endocrine Society’s annual meeting (ENDO 2025) in San Francisco, California, emphasized the importance of building lifelong bone strength during teen years to lessen the risk of bone-related complications.1

    Image credit: SoftSheep | stock.adobe.com

    “Obesity and early type 2 diabetes in adolescence don’t just affect weight or blood sugar—they can quietly interfere with bone development during the most critical years for building lifelong bone strength,” Fida Bacha, MD, lead researcher from Baylor College of Medicine in Houston, Texas, said in a news release. “That means teens with these health issues may face a greater risk of fractures and osteoporosis as they get older.”1

    Signs and Symptoms of Osteoporosis

    Osteoporosis causes bones to become so weak and brittle that small movements and even coughs can lead to a break. Although the condition typically does not show symptoms in its early stages, once the bones become weak, individuals may experience back pain, loss of height over time, a stooped posture, and a bone that breaks much more easily than expected.2

    Obesity and Type 2 Diabetes

    According to the CDC, around 1 in 5 children and adolescents ages 2 to 9 years that reside in the United States have obesity. For children, obesity is defined as a body mass index (BMI) at or above the 95th percentile for age and sex.3 Additionally, for children aged 5 years and under, overweight is defined as a weight-for-height measurement greater than 2 standard deviations above the WHO Child Growth Standards median. Obesity in this age group is when weight-for-height is greater than 3 standard deviations above the same median. For children and adolescents between 5 and 19 years old, overweight is defined by a BMI-for-age greater than 1 standard deviation above the WHO Growth Reference median, while obesity is greater than 2 standard deviations above this median.4

    An increase in children with obesity has led to more cases of T2D in younger individuals. Although it is not widely known why some children develop type 2 diabetes and some do not, common risk factors that increase its development include weight, inactivity, and diet—which are all closely related to overweight and obesity. To aid prevention, health care providers urge guardians to ensure their youth are eating healthy foods and are physically active.5

    “While adults with [T2D] are known to have increased risk of fractures, this has not been investigated in youth with type 2 diabetes,” Bacha said in the news release. “We wanted to understand how childhood obesity and early [T2D] affect bone health as children grow.”1

    Obesity and Type 2 Diabetes Link With Bone Health

    To further understand how obesity and T2D impact bone health in children and adolescents, researchers conducted a study that monitored 48 teenagers with an average age of 15.5 years. Of the total number of teens, 27% had normal weight, 31% were classified as overweight with normal blood sugar, and 42% had overweight and impaired blood sugar control, including 4 teens with prediabetes and 16 teens with T2D. The researchers measured body fat, fitness, blood sugar, and insulin levels for all teens included in the study. Additionally, they used high-resolution imaging to evaluate the teens’ bone structure and strength in the tibia and radius.1

    The results demonstrated that the teens with obesity showed less improvement in bone strength and quality over time compared with teens at a normal weight—and similar results were demonstrated among teens with T2D. These results were consistent in both the tibia and radius, as higher insulin levels seemed to contribute to less increase in bone strength.1

    The findings suggest teens with obesity and T2D could experience a greater risk of developing osteoporosis as they increase in age, emphasizing the importance of learning and continuing healthy habits and daily preventative steps to decrease their risk.1

    REFERENCES
    1. Obesity and type 2 diabetes in teen years can impair bone health. EuerkAlert!. News release. July 14, 2025. Accessed July 15, 2025. https://www.eurekalert.org/news-releases/1090293
    2. Osteoporosis. Mayo Clinic. News release. February 24, 2024. Accessed July 15, 2025. https://www.mayoclinic.org/diseases-conditions/osteoporosis/symptoms-causes/syc-20351968
    3. Childhood Obesity Facts. CDC. News release. April 2, 2024. Accessed July 15, 2025. https://www.cdc.gov/obesity/childhood-obesity-facts/childhood-obesity-facts.html
    4. Obesity and overweight. World Health Organization. May 7, 2025. Accessed July 15, 2025. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
    5. Type 2 Diabetes in Children. News release. November 18, 2023. Accessed July 15, 2025. https://www.mayoclinic.org/diseases-conditions/type-2-diabetes-in-children/symptoms-causes/syc-20355318

    Continue Reading